The Mark Foundation for Cancer Research Announces Global Expansion and $1M Funding Boost for Flagship Emerging Leader Award
The 12 New Drugs on the Horizon Presentation Titles for the AACR Annual Meeting 2026
Japan Approves Risovalisib For PIK3CA-Mutated Ovarian Clear Cell Carcinoma
Yvonne Awards 2026
Talha Badar: From Germline to Donor-Derived Mutations in MN
Thymic Health And Immunotherapy Outcomes In Patients With Cancer
Osimertinib Plus Chemotherapy Improves Outcomes in EGFR/TP53 mutant NSCLC: The TOP Study
Opening of the 2026 Mark Symposium - The Mark Foundation for Cancer Research
